Fabiënne van Puijfelik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Fabiënne van Puijfelik has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Marvin M. van Luijn
Department of Immunology, MS Center ErasMS, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
3 shared publications Janet de Beukelaar
Department of Neurology, Albert Schweitzer Hospital, Dordrecht, The Netherlands
2 shared publicationsJasper Rip
Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands; MS Center ErasMS, Erasmus MC, University Medical Center, Rotterdam, the Netherlands
2 shared publications- Joost Smolders
Department of Immunology, MS Center ErasMS, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
2 shared publications - Romy A. M. Klein Kranenbarg
MS Center ErasMS, Erasmus MC, University Medical Center, Rotterdam, the Netherlands; Department of Neurology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands; Department of Neurology, Albert Schweitzer Hospital, Dordrecht, the Netherlands
2 shared publications Anna C. Pelser
Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands; MS Center ErasMS, Erasmus MC, University Medical Center, Rotterdam, the Netherlands
1 shared publication
Latest Publications
- Open Access
- 6 June 2026
- Published by Elsevier in EBioMedicine
- Vol. 129, 106324
Refined single-cell profiling captures a CCR5high CD4+ cytotoxic T-cell precursor in multiple sclerosis
- 6 June 2026
- Published by Elsevier in EBioMedicine
- Vol. 129, 106324
Open AccessRefined single-cell profiling captures a CCR5high CD4+ cytotoxic T-cell precursor in multiple sclerosis
- Open Access
- 28 December 2023
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 6 (1) , fcae021
Ocrelizumab associates with reduced cerebrospinal fluid B and CD20dim CD4+ T cells in primary progressive multiple sclerosis
The anti-CD20 monoclonal antibody ocrelizumab reduces disability progression in primary progressive multiple sclerosis. CD20 is a prototypical B cell marker, however subpopulations of CD4+ and CD8+ T cells in peripheral blood and cerebrospinal fluid (CSF) also express low levels of CD20 (CD20dim). Therefore, direct targeting and depletion of these CD20dim T-cell-subpopulations may contribute to the therapeutic effect of ocrelizumab. The aim of this observational cohort study was to compare CD20+ B cell and CD20dim T cell distributions between peripheral blood and CSF of ocrelizumab-treated or untreated people with primary progressive multiple sclerosis. Ocrelizumab treatment was associated with depletion of circulating B cells and CD20dim CD4+ and CD20dim CD8+ T cells (P < 0.0001, P = 0.0016, and P = 0.0008, respectively), but in CSF only with lower proportions of B cells and CD20dim memory CD4+ T cells (P < 0.0001 and P = 0.0043, respectively). The proportional prevalence of CSF CD20dim memory CD8+ T cells was not significantly reduced (P = 0.1333). Only in CSF, the proportions of CD20dim cells within CD4+ and not CD8+ T cells positive for CCR5, CCR6 and CXCR3 were reduced in ocrelizumab-treated participants. The proportion of CD20dim CD4+ T cells and abundance of CD4+ relative to CD8+ T cells in CSF correlated positively with age (R = 0.6799, P = 0.0150) and Age Related Multiple Sclerosis Severity Score (R = 0.8087, P = 0.0014), respectively. We conclude that, in contrast to CSF CD20dim CD8+ T cells, B cells and CD20dim CD4+ T cells are reduced in CSF of people with primary progressive multiple sclerosis with an ocrelizumab-associated depletion of circulating B cells and CD20dim T cells. Therefore, these cells are likely to contribute to the therapeutic effects of ocrelizumab in people with primary progressive multiple sclerosis.
- 28 December 2023
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 6 (1) , fcae021
Open AccessOcrelizumab associates with reduced cerebrospinal fluid B and CD20dim CD4+ T cells in primary progressive multiple sclerosis
The anti-CD20 monoclonal antibody ocrelizumab reduces disability progression in primary progressive multiple sclerosis. CD20 is a prototypical B cell marker, however subpopulations of CD4+ and CD8+ T cells in peripheral blood and cerebrospinal fluid (CSF) also express low levels of CD20 (CD20dim). Therefore, direct targeting and depletion of these CD20dim T-cell-subpopulations may contribute to the therapeutic effect of ocrelizumab. The aim of this observational cohort study was to compare CD20+ B cell and CD20dim T cell distributions between peripheral blood and CSF of ocrelizumab-treated or untreated people with primary progressive multiple sclerosis. Ocrelizumab treatment was associated with depletion of circulating B cells and CD20dim CD4+ and CD20dim CD8+ T cells (P < 0.0001, P = 0.0016, and P = 0.0008, respectively), but in CSF only with lower proportions of B cells and CD20dim memory CD4+ T cells (P < 0.0001 and P = 0.0043, respectively). The proportional prevalence of CSF CD20dim memory CD8+ T cells was not significantly reduced (P = 0.1333). Only in CSF, the proportions of CD20dim cells within CD4+ and not CD8+ T cells positive for CCR5, CCR6 and CXCR3 were reduced in ocrelizumab-treated participants. The proportion of CD20dim CD4+ T cells and abundance of CD4+ relative to CD8+ T cells in CSF correlated positively with age (R = 0.6799, P = 0.0150) and Age Related Multiple Sclerosis Severity Score (R = 0.8087, P = 0.0014), respectively. We conclude that, in contrast to CSF CD20dim CD8+ T cells, B cells and CD20dim CD4+ T cells are reduced in CSF of people with primary progressive multiple sclerosis with an ocrelizumab-associated depletion of circulating B cells and CD20dim T cells. Therefore, these cells are likely to contribute to the therapeutic effects of ocrelizumab in people with primary progressive multiple sclerosis.
- Open Access
- 7 December 2023
- Published by Wiley in European Journal of Immunology
- Vol. 54 (2) , e2350544
Differential Runx3, Eomes, and T‐bet expression subdivides MS‐associated CD4+ T cells with brain‐homing capacity
Multiple sclerosis (MS) is a common and devastating chronic inflammatory disease of the CNS. CD4+ T cells are assumed to be the first to cross the blood–central nervous system (CNS) barrier and trigger local inflammation. Here, we explored how pathogenicity‐associated effector programs define CD4+ T cell subsets with brain‐homing ability in MS. Runx3‐ and Eomes‐, but not T‐bet‐expressing CD4+ memory cells were diminished in the blood of MS patients. This decline reversed following natalizumab treatment and was supported by a Runx3+Eomes+T‐bet− enrichment in cerebrospinal fluid samples of treatment‐naïve MS patients. This transcription factor profile was associated with high granzyme K (GZMK) and CCR5 levels and was most prominent in Th17.1 cells (CCR6+CXCR3+CCR4−/dim). Previously published CD28− CD4 T cells were characterized by a Runx3+Eomes−T‐bet+ phenotype that coincided with intermediate CCR5 and a higher granzyme B (GZMB) and perforin expression, indicating the presence of two separate subsets. Under steady‐state conditions, granzyme Khigh Th17.1 cells spontaneously passed the blood–brain barrier in vitro. This was only found for other subsets including CD28− cells when using inflamed barriers. Altogether, CD4+ T cells contain small fractions with separate pathogenic features, of which Th17.1 seems to breach the blood–brain barrier as a possible early event in MS.
- 7 December 2023
- Published by Wiley in European Journal of Immunology
- Vol. 54 (2) , e2350544
Open AccessDifferential Runx3, Eomes, and T‐bet expression subdivides MS‐associated CD4+ T cells with brain‐homing capacity
Multiple sclerosis (MS) is a common and devastating chronic inflammatory disease of the CNS. CD4+ T cells are assumed to be the first to cross the blood–central nervous system (CNS) barrier and trigger local inflammation. Here, we explored how pathogenicity‐associated effector programs define CD4+ T cell subsets with brain‐homing ability in MS. Runx3‐ and Eomes‐, but not T‐bet‐expressing CD4+ memory cells were diminished in the blood of MS patients. This decline reversed following natalizumab treatment and was supported by a Runx3+Eomes+T‐bet− enrichment in cerebrospinal fluid samples of treatment‐naïve MS patients. This transcription factor profile was associated with high granzyme K (GZMK) and CCR5 levels and was most prominent in Th17.1 cells (CCR6+CXCR3+CCR4−/dim). Previously published CD28− CD4 T cells were characterized by a Runx3+Eomes−T‐bet+ phenotype that coincided with intermediate CCR5 and a higher granzyme B (GZMB) and perforin expression, indicating the presence of two separate subsets. Under steady‐state conditions, granzyme Khigh Th17.1 cells spontaneously passed the blood–brain barrier in vitro. This was only found for other subsets including CD28− cells when using inflamed barriers. Altogether, CD4+ T cells contain small fractions with separate pathogenic features, of which Th17.1 seems to breach the blood–brain barrier as a possible early event in MS.